Cediel G, et al. – Researchers developed a clinical bedside tool for risk estimation of major adverse cardiovascular events (MACE) at 180 days for patients with type 2 myocardial infarction (MI) or myocardial injury. The derivation cohort consisted of 611 patients with type 2 MI or myocardial injury admitted to a tertiary hospital 2012-2013. MACE (death or readmission for heart failure or MI) was the primary outcome. The developed TARRACO Risk Score includes cardiac troponin (cTn) and clinical predictors of adverse cardiovascular events (ie, age, hypertension, absence of chest pain, dyspnea, and anemia). Overall, this novel risk score, based on bedside clinical variables and cTn concentrations, allows risk stratification for death and cardiac-related rehospitalizations. It identifies patients with the highest risk of adverse events, a subset of patients who can benefit from close observation, intensification of medicine, or both.